Compare ADMA Biologics Inc (ADMA) vs Comcast Corporation (CMCSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Comcast Corporation — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Comcast Corporation trades at $25.58 (market cap $89.43B). The key difference: Comcast Corporation is far larger — about 41× ADMA Biologics Inc's market cap, and Comcast Corporation pays a 5.24% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CMCSA | |
|---|---|---|
Market Cap | $2.18B | $89.43B |
Sector | Health | Media |
52-Week High | $20.38 | $32.50 |
52-Week Low | $7.60 | $21.92 |
Enterprise Value | $2.25B | $172.15B |
Dividend Yield | — | 5.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Comcast (CMCSA) trades at $25.36, up 0.75% today, with strong technical momentum showing bullish moving averages and support at $25. The company demonstrates robust fundamentals with a low P/E of 8.13 and consistent earnings beats, including Q2 2026 EPS of $1.04 versus $0.97 expected. Recent expansion announcements in Florida and New Hampshire highlight ongoing growth initiatives.
CMCSA presents compelling value with discounted valuation multiples and a 55.74% analyst buy rating. Key opportunities include wireless growth and Peacock profitability, while risks involve competitive pressures and the planned NBCUniversal spinoff. The consensus price target of $27.78 suggests 9.5% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →
